2-[methyl-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]ethyl (4-nitrophenyl) carbonate | 943349-37-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[methyl-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]ethyl (4-nitrophenyl) carbonate
• CAS: 943349-37-9
• 化学式: C₂₄H₂₉N₃O₈
• 分子量: 487.51
• InChiKey: UJWCRAKUYITQQB-FQEVSTJZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  12
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  140
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  2-[methyl-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]ethyl (4-nitrophenyl) carbonate 、 三氟乙酸 反应 0.5h， 生成
  参考文献：
  名称：

  WO2007/74170

  摘要：

  公开号：
• 作为产物：
  描述：

  tert-butyl N-[(2S)-1-[2-hydroxyethyl(methyl)amino]-1-oxo-3-phenylpropan-2-yl]carbamate 、 对硝基苯基氯甲酸酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以59%的产率得到2-[methyl-[(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]amino]ethyl (4-nitrophenyl) carbonate
  参考文献：
  名称：

  WO2007/74170

  摘要：

  公开号：

文献信息

• WO2007/74171
  申请人：——

  公开号：——

  公开（公告）日：——
• Compositions and methods for the treatment and prevention of disease
  申请人：Guichard Gilles

  公开号：US20070293469A1

  公开（公告）日：2007-12-20

  The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.
• Compositions and methods for the inhibition of phospholipase A2
  申请人：Guichard Gilles

  公开号：US20080031951A1

  公开（公告）日：2008-02-07

  The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use.
• Compositions and methods for synthesizing heterocyclic therapeutic compounds
  申请人：Guichard Gilles

  公开号：US20080033167A1

  公开（公告）日：2008-02-07

  Methods for the synthesis of various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and their pharmaceutically acceptable salt derivatives are provided. The compounds of the invention are useful as medicaments for the treatment or prevention of disease in a mammal, for example a human. In particular the compounds are useful as immunotherapeutics and anti-microbial drugs or vaccines. These heterocyclic derivatives can be used as an active agent in a pharmaceutical, as well as a diagnostic utility.
• Compositions and Methods For The Treatment and Prevention of Disease
  申请人：Guichard Gilles

  公开号：US20100291199A1

  公开（公告）日：2010-11-18

  The present invention relates to various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds, their pharmaceutically acceptable salt derivatives, and their methods of use. In one aspect the present invention relates to compositions and methods for the treatment and prevention of disease in a mammal comprising administering the compounds of the invention in a pharmaceutically acceptable form to a mammal. In particular, the invention relates to medicaments comprising various novel substituted dipeptide derived nitrogen-containing heterocyclic compounds and pharmaceutically acceptable salt derivatives and methods for administration to a mammal for the treatment and prevention of malarial diseases. The compounds of the invention may optionally be administered with at least one pharmaceutically acceptable excipient, another biologically active agent or a combination thereof.